Modelling Optimization and Control of Biomedical Systems

7 In vitro Studies: Acute Myeloid Leukaemia

Eirini G. Velliou¹, Eleni Pefani², Susana Brito dos Santos³, Maria Fuentes‐Gari⁴, Ruth Misener⁵, Nicki Panoskaltsis⁶, Athanasios Mantalaris³, Michael C. Georgiadis⁷, and Efstratios N. Pistikopoulos⁸

¹ Department of Chemical and Process Engineering, Faculty of Engineering and Physical Sciences, University of Surrey, UK

² Clinical Pharmacology Modelling and Simulation, GSK, UK

³ Department of Chemical Engineering, Imperial College London, UK

⁴ Process Systems Enterprise (PSE), London, UK

⁵ Department of Computing, Imperial College London, UK

⁶ Department of Medicine, Imperial College London, UK

⁷ Laboratory of Process Systems Engineering, School of Chemical Engineering, Aristotle University of Thesaloniki, Greece

⁸ Texas A&M Energy Institute, Artie McFerrin Department of Chemical Engineering, Texas A&M University, USA

7.1 Description of Biomedical System

This chapter describes human normal and abnormal (i.e., so‐called leukaemia) haematopoiesis, the latter being a severe cancer of the blood. The process of haematopoiesis – normal and abnormal – as well as the bone marrow (BM) architecture and the cell cycle procedure are analysed. Moreover, current experimental platforms for studying leukaemia ex vivo and parameters that have to be taken into consideration when designing a treatment protocol (i.e., chemotherapy) are discussed and analysed.

7.1.1 The Human Haematopoietic System

Haematopoiesis (or haemopoiesis) is the process of ...